Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (all subjects)~* Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.~* Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.~* A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.~* PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.~* PGA score of at least mild on scalp at SV1, SV2 and V1.~* A serum albumin-corrected calcium below the upper reference limit at SV2.~Inclusion Criteria (for subjects performing HPA axis assessment)~* Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.~* Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.~* PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.~* PGA score of at least moderate on scalp at SV1, SV2 and V1.~* Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH challenge).~Exclusion Criteria (all subjects):~* A history of hypersensitivity to any component of LEO 90100.~* Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp and/or body psoriasis within the following time period prior to V1 and during the trial:~  1. etanercept - within 4 weeks prior to V1~ 2. adalimumab, infliximab - within 2 months prior to V1~ 3. ustekinumab - within 4 months prior to V1~ 4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to V1~* Systemic treatment with therapies other than biologicals, with a possible effect on scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within 4 weeks prior to V1 or during the trial.~* PUVA therapy within 4 weeks prior to V1.~* UVB therapy within 2 weeks prior to V1 or during the trial.~Exclusion Criteria (for subjects performing HPA axis assessment):~* A history of serious allergy, allergic asthma or serious allergic skin rash.~* Known or suspected hypersensitivity to any component of CORTROSYN® (including ACTH/cosyntropin/tetracosactide)~* Systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to SV2 or during the trial.~* Oestrogen therapy (including contraceptives) or any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LEO 90100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).